Last reviewed · How we verify
NCT05191251
Retrospective Assessment of the Risk of Peripartum Hemorrhage in Pregnant Women : Retrospective Assessment of the Diagnostic Performance of the HEMSTOP Standardized Questionnaire
trial testing HEMSTOP questionnaire in Peripartum Period in 3,588 participants. Completed in 30 June 2022.
10 June 2022
Quick facts
| Lead sponsor | Brugmann University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,588 |
| Start date | 13 January 2022 |
| Primary completion | 10 June 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- HEMSTOP questionnaire
Conditions studied
- Peripartum Period — all drugs for Peripartum Period →
- Hemorrhage — all drugs for Hemorrhage →
- HEMSTOP Questionnaire — all drugs for HEMSTOP Questionnaire →
Sponsor
Brugmann University Hospital
Who can join
18 and older, female only, with Peripartum Period or Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The diagnostic performance of the HEMSTOP (Hematoma, hEmorrhage, Menorrhagia, Surgery, Tooth extraction, Obstetrics, Parents) standardized questionnaire collected during the preoperative anesthesia consultation in order to detect a deficit in hemostasis associated with the risk of hemorrhage in pregnant women will be analyzed. The primary aim of the study is to assess the sensitivity and the specificity of the HEMSTOP questionnaire to identity patients with an abnormal first-line hemostasis test requiring further development by performing second-line hemostasis tests. The second aim of the study is to assess the sensitivity and specificity of the HEMSTOP questionnaire in predicting postpartum hemorrhage.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Assessment of haemostasis in pregnant women: A retrospective evaluation of the diagnostic performance of the HEMSTOP standardised questionnaire.
Zec T, Schmartz D, Temmerman P, Fils JF, et al · · 2024 · cited 1× · PMID 39917607 · DOI 10.1097/ea9.0000000000000050
Verify or expand the search:
- PubMed search for NCT05191251
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Brugmann University Hospital trials
Trials by the same sponsor.
- NCT07267403 — Comparison of Modulations of Motor Brain Activity and SedLine After Median Nerve Stimulation in General Anesthesia · NA · recruiting
- NCT07267416 — Impact of Combined PSi + NIRS Monitoring in the Prevention of Postoperative Cognitive Disorders in Cardiac Surgery. · NA · recruiting
- NCT07413315 — Benefits of a Renal Rehabilitation Program Adapted to Uremic Patients on Daily Hemodialysis at Low Dialysate Flow Rate. · NA · recruiting
- NCT06292377 — Better Understanding of Fatigue After STroke · NA · recruiting
- NCT06160232 — Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05191251 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brugmann University Hospital
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05191251.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing